Is Molecular Mimicry between hPF4 and SARS-CoV-2 Spike Protein a Potential Basis for Autoimmune Responses in Vaccinated and Naturally Infected Patients?

Sergio Carnevale, MD1  Marta Giovanetti, PhD2  Domenico Benvenuto, MD3  Massimo Ciccozzi, BSc3  Francesco Broccolo, MD, BSc4,5

1 Cerba HealthCare Italia, Section of Anatomic Pathology, Milan, Italy  
2 Laboratório de Flavivírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil  
3 Medical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy  
4 Department of Medicine and Surgery, School of Medicine, University of Milano-Bicocca, Monza, Italy  
5 Cerba HealthCare Italia, Milan, Italy

Address for correspondence  Francesco Broccolo, MD, BSc,  
Department of Medicine and Surgery, School of Medicine, University of Milano-Bicocca, Monza, Italy  
(e-mail: francesco.broccolo@unimib.it; broccolo5@gmail.com).

Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will hopefully terminate the pandemic of coronavirus disease 2019 (COVID-19) and several vaccines are now available. The European Medical Agency has approved four vaccines1 for the prevention of symptomatic COVID-19: two messenger RNA (mRNA)–based vaccines (mRNA BNT162b2-BioNTech/Pfizer and mRNA-1273-Moderna) encoding the spike protein antigen of SARS-CoV-2 and two recombinant adenoviral vector–based vaccines (ChAdOx1-AstraZeneca and Ad26.COV2.S -Janssen) encoding the spike glycoprotein of SARS-CoV-2.

In Europe since March 2021, ~100 patients2 with venous thromboses at unusual sites (cerebral venous sinus thrombosis and splanchic vein thrombosis) in combination with moderate-to-severe thrombocytopenia were observed in individuals within 1 month from the vaccination with the ChAdOx1 nCoV-19 COVID-19 vaccine.3–5 Similar complications have also been reported after vaccination with the Ad26.COV2.S Janssen COVID-19 vaccine.6,7 Known as vaccine-induced immune thrombocytopenic purpura (VIT) or thrombosis with thrombocytopenia syndrome,8 the condition presents with thromboses, often at unusual sites, low platelet count, high D-dimer, and high levels of anti-platelet factor 4 (anti-PF4) antibodies,4,9,10 which are otherwise usually seen in patients with heparin induced thrombocytopenia or autoimmune HIT.11 It is currently unknown what triggers the formation of these antibodies after vaccination against COVID-19.

Recent findings, especially considering the clinical profile, suggest the production of two types of antibodies, as described elsewhere.11 These different types of antibodies, analogous to the reference monoclonal IgG2αK (designated KKO) and anti-PF4 (designated RTO) antibodies monoclonal antibodies,11 are directed against overlapping, yet different epitopes of human PF4. KKO-like antibodies were found to induce an autoimmune response in heparin-treated patients that results in thrombocytopenia and a prothrombotic state, while RTO-like antibodies do not promote platelet activation and thrombosis.11 This response was observed in ChAdOx1 n-CoV-19-vaccinated people and might be occurring in COVID-19 patients as well, since a prothrombotic state with thrombocytopenia was observed in patients with thrombotic complications of the pulmonary and gastroenteric districts.12

Considering this background, human PF4 (hPF4; Reference Sequence: NG032897) and surface spike glycoprotein (Reference Sequence: YP_009724390.1) have been downloaded from NCBI genome database and manually edited using BioEdit.13 Subsequently Swiss-Model14 and HHpred15 online web-tools have been used to identify eventual amino-acidic domains showing homology or similarity between the two protein structures. For this purpose, the BepiPred 2.0 online tool has been used to survey eventual common B cells epitopes.16 The performed analyses did not show any statistically significant homologies or similarities between the...
hPF4 and the spike glycoprotein structures and no potentially overlapping B cell epitope was found. These results suggest that probably the molecular mimicry between the hPF4 and the SARS-CoV-2 spike protein is not responsible for the prothrombotic events associated with VITT. However, binding experiments with KKO monoclonal antibody against the spike by using both surface plasmon resonance and immunoprecipitation should be performed to confirm this evidence.

Previous articles have highlighted how SARS-CoV-2 can directly activate platelets and trigger procoagulant events. Moreover, they suggested the possibility of cross-reactivity between antivector antibodies and PF4.17 Probably this rare emergent autoimmune response can be induced by the cross-reaction with the adenovirus that brings viral DNA and PF4 together in the extracellular space inducing a possible reaction with antigen presenting cells.17 This potentially explains why thrombotic complications in patients vaccinated with mRNA-lipid nanoparticle are less frequent compared with adenovirus as vaccine vector. Further investigations are needed to clarify the safety of adenoviral vector vaccines in patients with risk factors for thrombosis or chronic thrombocyte disorders.17

Conflict of Interest
None declared.

References